NanoViricides, Inc. (NNVC)
1.44
-0.07
(-4.64%)
USD |
NYAM |
Oct 22, 15:41
NanoViricides Net Income (Quarterly) : -2.223M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.223M |
| March 31, 2026 | -1.989M |
| December 31, 2025 | -2.221M |
| September 30, 2025 | -1.785M |
| June 30, 2025 | -2.096M |
| March 31, 2025 | -2.217M |
| December 31, 2024 | -2.028M |
| September 30, 2024 | -3.127M |
| June 30, 2024 | -2.356M |
| March 31, 2024 | -1.854M |
| December 31, 2023 | -2.115M |
| September 30, 2023 | -1.969M |
| June 30, 2023 | -3.57M |
| March 31, 2023 | -1.703M |
| December 31, 2022 | -1.745M |
| September 30, 2022 | -1.571M |
| June 30, 2022 | -1.78M |
| March 31, 2022 | -1.793M |
| December 31, 2021 | -1.921M |
| September 30, 2021 | -2.613M |
| June 30, 2021 | -2.073M |
| March 31, 2021 | -2.108M |
| December 31, 2020 | -2.330M |
| September 30, 2020 | -2.311M |
| June 30, 2020 | -1.875M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.083M |
| December 31, 2019 | -1.928M |
| September 30, 2019 | -1.561M |
| June 30, 2019 | -2.212M |
| March 31, 2019 | -2.140M |
| December 31, 2018 | -2.231M |
| September 30, 2018 | -1.842M |
| June 30, 2018 | -1.651M |
| March 31, 2018 | -2.11M |
| December 31, 2017 | -2.797M |
| September 30, 2017 | -2.006M |
| June 30, 2017 | -2.558M |
| March 31, 2017 | -3.139M |
| December 31, 2016 | -1.546M |
| September 30, 2016 | -3.061M |
| June 30, 2016 | -1.651M |
| March 31, 2016 | -4.992M |
| December 31, 2015 | -2.775M |
| September 30, 2015 | -1.307M |
| June 30, 2015 | -0.9177M |
| March 31, 2015 | -0.251M |
| December 31, 2014 | -1.881M |
| September 30, 2014 | -0.2391M |
| June 30, 2014 | -5.342M |
| March 31, 2014 | 1.324M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 2.223M |
| EPS Diluted (Quarterly) | -0.0996 |
| Enterprise Value | 31.95M |
| Earnings Yield | -28.34% |
| Normalized Earnings Yield | -28.34 |